Replacement therapy for hypothyroidism in special groups of patients
https://doi.org/10.62751/2713-0177-2024-5-3-04
Abstract
Primary hypothyroidism is one of the most common endocrine diseases. The replacement therapy with levothyroxine is indicated to all patients with overt hypothyroidism. Modern tablet preparations of levothyroxine provide easy administration, simplicity of selection of the drug dose. At the same time, a fairly large number of patients who have been receiving levothyroxine preparations for a long time are in a state of decompensation. The reasons for decompensation may be low patient adherence, receiving of drugs or gastrointestinal pathology, which can affect the bio-availability of levothyroxine. This review is devoted to the discussion of the problem of decompensation of hypothyroidism and the influence of patient’s adherence on the efficacy of replacement therapy.
About the Authors
T. B. Morgunova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Tatyana B. Morgunova – Candidate of sciences (PhD) in medicine, Associate Professor, Department of Endocrinology No.1
Moscow
E. G. Ryzhkova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Ekaterina G. Ryzhkova – Posrgraduate student, Department of Endocrinology No.1
Moscow
M. I. Strokova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Marina I. Strokova – resident, Department of Endocrinology No.1
Moscow
V. V. Fadeyev
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Valentin V. Fadeyev – Doctor of medical sciences, Professor, Сorresponding member of the RAS, Head, Department of Endocrinology No.1
Moscow
References
1. Vanderpump MP, Tunbridge WM, French JMet al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995; 43(1): 55–68. doi: 10.1111/j.1365-2265.1995.tb01894.x.
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4): 526–34. doi: 10.1001/archinte.160.4.526.
3. Sichieri R, Baima J, Marante T et al. Low prevalence of hypothyroidism among black and Mulatto people in a population-based study of Brazilian women. Clin Endocrinol (Oxf). 2007; 66(6): 803–7. doi: 10.1111/j.1365-2265.2007.02816.x.
4. Jonklaas J, Bianco AC, Bauer AJ et al.; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: Prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12):1670–751. doi: 10.1089/thy.2014.0028.
5. Pearce SH, Brabant G, Duntas LH et al. 2013 ETA guideline: Management of subclinical hypothyroidism. Eur Thyroid J. 2013; 2(4): 215–28. doi: 10.1159/000356507.
6. Perez CL, Araki FS, Graf H, de Carvalho GA. Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid. 2013 Jul;23(7):779-84. doi: 10.1089/thy.2012.0435.
7. Okosieme OE, Belludi G, Spittle K et al. Adequacy of thyroid hormone replacement in a general population. QJM. 2011; 104(5): 395–401. doi: 10.1093/qjmed/hcq222.
8. Flynn RW, Bonellie SR, Jung RT et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010; 95(1): 186–93. doi: 10.1210/jc.2009-1625.
9. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489–99. doi: 10.1210/jcem.87.2.8182.
10. Vaisman F, Coeli CM, Ward LS et al. How good is the levothyroxine replacement in primary hypothyroidism patients in Brazil? Data of a multicentre study. J Endocrinol Invest. 2013; 36(7): 485–88. doi: 10.3275/8810.
11. Díez JJ. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci. 2002; 57(5): M315–20. doi: 10.1093/gerona/57.5.m315.
12. Benvenga S, Bartolone L, Squadrito S et al. Delayed intestinal absorption of levothyroxine. Thyroid. 1995; 5(4): 249–53. doi: 10.1089/thy.1995.5.249.
13. Crilly M. Thyroxine adherence in primary hypothyroidism. Lancet. 2004; 363(9420): 1558. doi: 10.1016/S0140-6736(04)16172-2.
14. Ducharme M, Scarsi C, Bettazzi E et al. A Novel levothyroxine solution results in similar bioavailability whether taken 30 or just 15 minutes before a high-fat high-calorie meal. Thyroid. 2022; 32(8): 897–904. doi: 10.1089/thy.2021.0604.
15. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011; 21(5): 483–86. doi: 10.1089/thy.2010.0296.
16. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;2 8(4): 437–43. doi: 10.1592/phco.28.4.437.
17. McMillan M, Rotenberg KS, Vora K et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy: Results of the CONTROL surveillance project. Drugs R D. 2016; 16(1): 53–68. doi: 10.1007/s40268-015-0116-6.
18. Kumar R, Shaukat F. Adherence to levothyroxine tablet in patients with hypothyroidism. Cureus. 2019; 11(5) :e4624. doi: 10.7759/cureus.4624.
19. Effraimidis G, Watt T, Feldt-Rasmussen U. Levothyroxine therapy in elderly patients with hypothyroidism. Front Endocrinol (Lausanne). 2021; 12: 641560. doi: 10.3389/fendo.2021.641560.
20. Livecchi R, Coe AB, Reyes-Gastelum D et al. Concurrent use of thyroid hormone therapy and interfering medications in older US veterans. J Clin Endocrinol Metab. 2022; 107(7): e2738–42. doi: 10.1210/clinem/dgac216.
21. Somwaru LL, Arnold AM, Joshi N et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009; 94(4):1342–45. doi: 10.1210/jc.2008-1696.
22. Bornikowska K, Gietka-Czernel M, Raczkiewicz D et al. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: An observational study. J Clin Med. 2021; 10(22): 5233. doi: 10.3390/jcm10225233.
23. Antonelli A, Elia G, Ragusa F et al. The stability of TSH, and thyroid hormones, in patients treated with tablet, or liquid levothyroxine. Front Endocrinol (Lausanne). 2021; 12: 633587. doi: 10.3389/fendo.2021.633587.
24. Virili C, Giovanella L, Fallahi P et al. Levothyroxine therapy: Changes of TSH levels by switching patients from tablet to liquid formulation. A Systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018; 9: 10. doi: 10.3389/fendo.2018.00010.
25. Laurent I, Tang S, Astere M et al. Liquid L-thyroxine versus tablet L-thyroxine in patients on L-thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018; 61(1): 28–35. doi: 10.1007/s12020-018-1574-8.
26. Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: Should this formulation still be considered as the first-line therapy? Endocrine. 2020; 67(2): 281–90. doi: 10.1007/s12020-019-02185-4.
Review
For citations:
Morgunova T.B., Ryzhkova E.G., Strokova M.I., Fadeyev V.V. Replacement therapy for hypothyroidism in special groups of patients. FOCUS. Endocrinology. 2024;5(3):30-35. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-3-04
Views:
94
Email this article 